Tatva Chintan Pharma Chem shares listing gain: Stock makes stellar market debut with nearly 120% premium – Check Anil Singhvi's STRATEGY going forward

Tatva Chintan Pharma and Chem made its debut on the stock market with bumper listing gains, and above Zee Business Managing Editor and the market guru Anil Singhvi expectations. The company’s issue was oversubscribed 180 times in the three-day from July 16-20, 2021.

Tatva Chintan got listed almost 120 per cent higher premium at Rs 2371 per share on both NSE and BSE as compared to Rs 1083 per share issue price at the higher band. Singhvi had predicted that Tatva Chintan may list between 2100-2300 per share on the exchanges today.

See Zee Business Live TV Streaming Below:

The shares of Tatva Chintan made a lifetime high of Rs 2534 per share on the NSE, while on the BSE it touched Rs 2486 per share as a record high during its start of the journey on the exchanges. On NSE, the counter touched an upper circuit with new all-time high levels.

Singhvi suggests, short-term investors keep a stop loss of Rs 2200 per share, while for long-term investors he suggests to Hold the stock.

तत्व चिंतन फार्मा की बंपर लिस्टिंग...

इश्यू प्राइस ₹1083 के मुकाबले NSE पर ₹2111.85 और BSE पर ₹2111.80 पर लिस्ट#TatvaChintanPharma #TatvaChintanPharmaIPO #NewListing @AnilSinghvi_ pic.twitter.com/xpAs789Slm

— Zee Business (@ZeeBusiness) July 29, 2021

Tatva Chintan IPO by far is most lucrative in terms of applications as Reliance Power has garnered such attention once, Singhvi said during the speciality chemical company’s listing. 

The issue size of the company was at Rs 500 crore, of which there is a fresh Issue of up to Rs 225 cr and an Offer for Sale (OFS) of up to Rs 275 crore.

The portion meant for qualified institutional buyers(QIBs) was subscribed 185.23 times, those reserved for non-institutional investors a whopping 512.22 times and retail individual investors (RIIs) quota received 35.35 times subscription.

The managing editor has said, “One should consider subscribing to this issue as there is a huge action in this sector (speciality chemical) these days. One could apply in this IPO for both good listing gain and with the long-term objective.”